NeuroHarmonics

NeuroHarmonics operates at the intersection of neurotechnology, medical devices and clinical research, with a stated emphasis on non-invasive neuromodulation for therapeutic applications. Its differentiator is the use of focused ultrasound to target deep brain circuits without surgery or implanted hardware, potentially addressing an access and reversibility challenge associated with invasive deep-brain stimulation. The company also combines product-oriented neurotechnology work with a structured research archive covering transcranial and peripheral ultrasound, protocols, devices and acoustic parameters. That combination gives it a research-infrastructure angle in addition to a therapeutic-device ambition. NeuroHarmonics should instead be viewed as an early-stage specialist alongside broader focused-ultrasound and neuromodulation developers, rather than as an established commercial platform. Its seed-stage status, four current positions and two granted patents suggest technical differentiation is still being converted into clinical, regulatory and market evidence. The principal competitive questions are whether its ultrasound systems can demonstrate reliable deep-target precision, therapeutic efficacy, safety and scalable deployment relative to implanted stimulation and other non-invasive neuromodulation approaches.

NeuroHarmonics appears to be progressing from formation and technical development toward early financing and team building. The company was founded in 2024, and its core founding team members began their recorded roles in June 2024. The next clear inflection point was the seed round announced on Jan 1, 2026, with Fusion Fund identified as the investor; the financing amount is not publicly available. The business now has four current positions, including the CEO, CTO, a neurotech engineer and a founding engineer, while maintaining a careers page that signals ongoing recruitment. Its development trajectory is centered on focused-ultrasound neuromodulation for deep brain circuits, supported by a research archive covering transcranial and peripheral ultrasound techniques. Two granted patents provide an early intellectual-property base, but there is no disclosed valuation, financing amount, clinical trial result, named commercial product or product-launch history. As a result, growth is more visible in capital formation, staffing and technical positioning than in revenue or market adoption. The next meaningful indicators will be disclosed device or platform milestones, clinical validation, regulatory progress, additional hires and evidence that the research infrastructure supports repeatable therapeutic applications.